omega-Chloroacetophenone (Mace)

A potent eye, throat, and skin irritant. One of its uses is as a riot control agent.

Also Known As:

Mace; Chloroacetophenone; 2-Chloro-1-phenylethanone; 3'-Chloroacetophenone; Chloracetophenone; 2 Chloro 1 phenylethanone; 2 Chloroacetophenone; 3' Chloroacetophenone; alpha Chloroacetophenone; omega Chloroacetophenone; 2-Chloroacetophenone; alpha-Chloroacetophenone; Ethanone, 2-chloro-1-phenyl-

Networked: 8905 relevant articles (270 outcomes, 1279 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Ketones: 2618
  - Acetophenones: 16
    - omega-Chloroacetophenone: 8905
      - 4-chloroacetophenone
      - pentachloroacetophenone

Experts

1.	Jeong, Myung Ho: 148 articles (05/2022 - 09/2003)
2.	Serruys, Patrick W: 132 articles (01/2022 - 02/2002)
3.	Mehran, Roxana: 116 articles (03/2022 - 05/2002)
4.	Stone, Gregg W: 109 articles (02/2022 - 05/2002)
5.	Colombo, Antonio: 96 articles (01/2021 - 02/2002)
6.	Xu, Bo: 88 articles (02/2022 - 08/2005)
7.	Ahn, Youngkeun: 75 articles (03/2022 - 10/2006)
8.	Bhatt, Deepak L: 73 articles (10/2022 - 01/2002)
9.	Jang, Yangsoo: 68 articles (05/2022 - 02/2006)
10.	Waksman, Ron: 66 articles (11/2022 - 01/2002)

Related Diseases

1.	Cardiovascular Diseases (Cardiovascular Disease) 10/01/2016 - "Even with the most stringent experimental control to reduce bias-introducing factors, studies with hard primary clinical endpoints such as the occurrence of major adverse cardiac events (MACE) or target-lesion revascularization (TLR) rates remain the gold standard, with numbers reaching into the 300-700 patient range per group. " 10/01/2016 - "Complete revascularization was associated with a reduced risk of major adverse cardiac events (MACE) (RR 0.61, 95% CI 0.45-0.81, P < 0.001), due to a significant reduction in urgent revascularization (RR 0.46, 95% CI 0.29-0.70, P < 0.001). " 11/15/2017 - "In its proof of concept application to DEFER lesions with FFR ≥ 0.75, the 28 with pb-CFR < 2 compared to 28 with pb-CFR ≥ 2 had a non-significant reduction in freedom from angina (61% vs. 71% at 5 years, P = 0.57) and a non-significantly higher rate of major adverse cardiac events (MACE, 25% vs. 15%, P = 0.34). " 08/29/2017 - "Compared to the angiography guidance, IVUS-guided DES implantation was associated with a significant reduction in the major adverse cardiac events (MACE) (OR 0.60, 95% CI 0.46-0.78; P < 0.001), target vessel revascularization (OR 0.60, 95% CI 0.40-0.91; P = 0.02) and target lesion revascularization (OR 0.60, 95% CI 0.42-0.85; P = 0.004). " 01/01/2017 - "The risk of MACE is significantly greater in patients with T2DM, without clinical cardiovascular disease, who have both a longer diabetes duration and significant CAS, compared with those who have a shorter duration and/or nonsignificant CAS."
2.	Myocardial Infarction 01/01/2021 - "Overall meta-analysis with inclusion of the 5-year results from the EXCEL trial using the protocol definition for myocardial infarction showed that CABG is associated with a significant reduction in the risk of major adverse cardiovascular events (MACE) (risk ratio = 0.74; 95% confidence interval = 0.68-0.80). " 11/01/2020 - "Nonetheless, significant reduction in all-cause mortality, cardiac mortality, myocardial infarction, MACE, and MACCE has not been demonstrated in the subgroups analysis of randomized trials. " 09/01/2023 - "The results demonstrated a significant reduction in the risk of major adverse cardiovascular events (MACE), myocardial infarction, CV mortality, and all-cause mortality. " 12/20/2021 - "Incorporation of HUA to the thrombolysis in myocardial infarction (TIMI) score yielded a significant improvement in discrimination for MACE. " 12/01/2021 - "When adding LT3S to the thrombolysis in myocardial infarction (TIMI) risk score, the combined model yielded a significant improvement in discrimination for MACE. "
3.	ST Elevation Myocardial Infarction 08/01/2020 - "The findings of this meta-analysis suggest that in patients with STEMI and MVD, complete revascularization is superior to culprit-only PCI in reducing the risk of MACE outcomes, including cardiovascular mortality, without increasing the risk of adverse safety outcomes." 01/01/2016 - "This study shows that among STEMI patients undergoing primary PCI EES, as compared to SES, is associated with significant reduction in MACE and ST at long-term follow-up." 01/01/2022 - "Compared with AT, intracoronary-administered thrombolytics significantly improved myocardial perfusion and MACE in STEMI patients." 04/01/2021 - "Low-risk STEMI patients stratified by Zwolle risk score, who were treated successfully with PPCI, experienced low 30-day MACE and mortality rates, indicating that early discharge may be safe in these patients. " 01/01/2021 - "In contrast to the culprit-only approach, MVR in patients with STEMI is associated with a significant reduction in MACE, angina and need for revascularization."
4.	Hemorrhage 01/01/2019 - "The use of DES compared with BMS was associated with a significant reduction in MACE (odds ratio [OR]:0.76; 95% confidence interval [CI]:0.62-0.93; P = 0.007) with no increased risk of bleeding events (OR: 1.07; 95% CI: 0.89-1.27; P = 0.48). " 01/01/2018 - "The addition of NOACs to SAP did not result in significant reduction of MACE or increase in clinically significant bleeding." 01/01/2017 - "Our meta-analysis shows that among ACS patients undergoing PCI, the radial approach is associated with a significant reduction in mortality, major bleeding complications, MACE and vascular complication compared with the femoral approach." 12/01/2016 - "TRA compared with TFA in ACS patients undergoing invasive management was associated with a significant reduction in the risk of mortality (RR=0.72; 95% CI: 0.59-0.88; P=0.002), major bleeding (RR 0.48; 95% CI: 0.37-0.61; P<0.00001) and MACE (RR 0.81; 95% CI: 0.69-0.96; P=0.01), with similar procedural rate of success. " 09/01/2014 - "At 30 days, TRA compared to TFA was associated with a significant reduction of cardiovascular mortality (5.2% vs 10.5%; P<.001), significant MACE reduction (7.3% vs 12.5%; P<.001), fewer access-site complications (0.9% vs 8.2%; P<.001), and lower TIMI major bleeding (1.1% vs 4.3%; P<.001). "
5.	Stroke (Strokes) 06/01/2023 - "Using a pooled analysis, CPD was associated with a significant reduction in major adverse cardiovascular events MACE (OR 0.75, 95% CI 0.70-0.81, P < 0.01), mortality (OR 0.65, 95% CI 0.58-0.74, P < 0.01) and stroke (OR 0.84, 95% CI 0.76-0.93, P < 0.01) in patients undergoing TAVI. " 01/01/2023 - "After IPTW, the results demonstrated that the combined treatment was associated with a significantly reduced incidence of MACE (hazard ratio [HR] 0.79, 95% conidence interval [CI] 0.72-0.87) and stroke (HR 0.48, 95% CI 0.42-0.54) but not of MI (HR 1.03, 95% CI 0.92-1.15) or all-cause mortality (HR 0.93, 95% CI 0.64-1.37). " 01/01/2023 - "SGLT2is reduce MACE without any discernable significant reduction of the incidence of MI or stroke (fatal and nonfatal), probably implicating mechanisms unrelated to anti-atherogenic effects." 01/01/2022 - "The risk of MACE and its component also improved significantly except for stroke. " 01/01/2022 - "In the subgroup analysis, omega-3 FA supplementation decreased the incidence of MACE and cardiovascular death in acute patients with MI, the risk of MI and stroke in patients with CHD, and the risk of MI in patients with high-risk CHD. "

Related Drugs and Biologics

1.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
2.	Clopidogrel (Plavix)
3.	oxidized low density lipoprotein
4.	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))
5.	Colchicine
6.	Ticagrelor
7.	Prasugrel Hydrochloride
8.	Tirofiban (Aggrastat)
9.	Aspirin (Acetylsalicylic Acid)
10.	C-Reactive Protein

Related Therapies and Procedures

1.	Stents
2.	Therapeutics
3.	Percutaneous Coronary Intervention
4.	Drug-Eluting Stents
5.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)